Farxiga extended in the US to reduce risk of cardiovascular death and hospitalisation for heart failure to a broader range of patients
FDA approval means patients with heart failure can benefit from Farxiga regardless of left ventricular ejection fraction status.AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA) was based on positive results from the DELIVER Phase III trial.[1] Farxiga was previously approved in the US for adults with HF with reduced ejection fraction (HFrEF). Ruud Dobber, Executive Vice-